

Review

A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors

Anna Izzo, Elena Massimino, Gabriele Riccardi and Giuseppe Della Pepa *

Department of Clinical Medicine and Surgery, Federico II University, Via Sergio Pansini 5, 80131 Naples, Italy; ariannaizzo.1991@gmail.com (A.I.); elenamassimino@libero.it (E.M.); riccardi@unina.it (G.R.)

* Correspondence: gdp0206@libero.it; Tel.: +39-081-746-2166

Abstract: Type 2 diabetes mellitus (T2DM) represents a major health burden for the elderly population, affecting approximately 25% of people over the age of 65 years. This percentage is expected to increase dramatically in the next decades in relation to the increased longevity of the population observed in recent years. Beyond microvascular and macrovascular complications, sarcopenia has been described as a new diabetes complication in the elderly population. Increasing attention has been paid by researchers and clinicians to this age-related condition—characterized by loss of skeletal muscle mass together with the loss of muscle power and function—in individuals with T2DM; this is due to the heavy impact that sarcopenia may have on physical and psychosocial health of diabetic patients, thus affecting their quality of life. The aim of this narrative review is to provide an update on: (1) the risk of sarcopenia in individuals with T2DM, and (2) its association with relevant features of patients with T2DM such as age, gender, body mass index, disease duration, glycemic control, presence of microvascular or macrovascular complications, nutritional status, and glucose-lowering drugs. From a clinical point of view, it is necessary to improve the ability of physicians and dietitians to recognize early sarcopenia and its risk factors in patients with T2DM in order to make appropriate therapeutic approaches able to prevent and treat this condition.

Keywords: sarcopenia; type 2 diabetes mellitus; skeletal muscle mass



check for updates

Citation: Izzo, A.; Massimino, E.; Riccardi, G.; Della Pepa, G. A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors. *Nutrients* **2021**, *13*, 183. <https://doi.org/10.3390/nu13010183>

Received: 5 December 2020

Accepted: 7 January 2021

Published: 9 January 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Type 2 diabetes mellitus (T2DM) is one of the most widespread metabolic diseases. The alarming rise in T2DM prevalence worldwide, exploding in both low-income countries and adolescents/young adults, as well as its heavy impact on longevity and quality of life, poses enormous challenges in the diagnosis, prevention, and treatment of this disease [1]. The improvement of the healthcare system and the advancements in prevention and treatment of major non-communicable illnesses have substantially increased the longevity of the population. Since advancing age represents a risk factor for T2DM and the improvement of health care has contributed to reduced mortality also in the diabetic population, the number of elderly people with T2DM has increased dramatically in recent years [2,3]. T2DM represents an important health burden in the elderly population, affecting approximately 25% of people over the age of 65 years; this proportion is expected to further increase in the next decades [4]. Beyond microvascular and macrovascular complications, elderly people with T2DM have higher rates of functional disability, coexisting illnesses, and several common geriatric disorders [5]. Among these, sarcopenia—a degenerative skeletal muscle condition related to the aging process—has been described as a new complication observed in the elderly population with T2DM [6].

Sarcopenia was defined for the first time in 1988 by Irwin Rosenberg as an age-related decrease in skeletal muscle mass and function [7], and ten years later Baumgartner provided a method for the evaluation of sarcopenia by using appendicular lean mass adjusted for height (kg/m^2) [8].

From a physiological point of view, a progressive and generalized loss of muscle mass can be observed after the age of 40 years; the rate of deterioration has been estimated to be 8% every ten years up to 70 years, and 15–25% every ten years after this age [9]. Similarly, a 10–15% loss of leg strength every ten years has been reported to occur up to 70 years, increasing to 25–40% every ten years after this age [10]. Despite the clear notion of sarcopenia, its current evaluation in clinical practice is still not univocal. This gap is strictly related to the fact that evaluation of muscle strength, mass, quality, and performance should comprehensively be taken into account for the definition of sarcopenia.

In recent years, different definitions by international consensus have been proposed. In 2010, the European Working Group on Sarcopenia in Older People developed a practical clinical definition and consensus diagnostic criteria for sarcopenia recommending to utilize the presence of both low muscle mass and low muscle function (strength or performance) [11]. In 2018, an update by the same working group was provided defining sarcopenia by low measurement levels of three parameters: muscle strength (evaluated by hand grip strength), muscle quantity/quality (evaluated by appendicular lean mass or skeletal muscle mass), and physical performance (evaluated by gait speed or short physical performance battery) as an indicator of severity [12]. Similarly, the Asian Working Group for Sarcopenia developed its own consensus—the only difference being in cut-off values, in consideration of the anthropometric characteristics of the Asian population [13]. Reduction in muscle mass and physical performance were included in the definition of sarcopenia by the International Working Group on Sarcopenia [14], while reduction in muscle mass and strength were included in the diagnostic criteria proposed by the American Foundation for the National Institutes of Health [15].

The prevalence of sarcopenia worldwide ranges from 10% to 40%, based on the different characteristics of the population and the different criteria to assess it [16]. In non-Asian countries, the prevalence is higher than in Asian ones, without differences between genders [17]. Furthermore, the prevalence of sarcopenia is higher in acutely hospitalized older patients [18] or in patients admitted to post-acute geriatric rehabilitation [19]. In fact, sarcopenia is associated with poor health outcomes—such as cognitive impairment and functional decline [20,21], depression [22], falls and fractures [23], and mortality [21]—and can be considered the main physical drivers of frailty or perhaps even a precursor state. Sarcopenia and frailty are strictly related and lead to difficulties performing daily living activities and increased disability [24]. Frailty is a condition in which the individual is highly vulnerable to stressors that lead to disability, dependency, and mortality with decreased physical reserves [25,26]. The most common definition used for frailty is the frailty phenotype, consisting of five physical components to define frailty: unintentional weight loss, self-reported exhaustion, weakness, slow walking speed, and low physical activity [27]. Individuals are considered to be frail when they meet three or more criteria, and they are considered to be robust when they have none. The Frailty Index is another popular approach describing frailty as a state caused by the accumulation of health deficits during the life course. It is calculated as the ratio of the number of deficits present in the individual to the number of total deficits considered [28]. The Edmonton Frail Scale (EFS) [29], its recent validated short version (EFS-SF) [30,31], the Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight (FRAIL) Score [32], the Geriatricians' Clinical Impression of Frailty (GCIF) scale [33], and the Clinical-Functional Vulnerability Index-20 (IVCF-20) [34] are other approaches able to identify frailty.

It is important to underline that the progressive increase in obesity worldwide configures a new public health problem: sarcopenic obesity, a condition in which sarcopenia and obesity are coexisting [35]. Sarcopenic obesity might be related to different factors such as aging, reduction in physical activity, malnutrition, sub-clinical inflammation, and hormonal changes [36]. Dramatically, the clinical consequences of sarcopenic obesity are much greater than sarcopenia alone; in fact, several studies reported that sarcopenic obesity is associated with higher fasting blood glucose, insulin resistance, blood pressure,

plasma lipid abnormalities, T2DM, cardiovascular diseases, and mortality compared with sarcopenia or obesity alone [35,37–39].

Sarcopenia has received growing interest over the last decade—it is now recognized as an independent condition by the International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM), code (i.e., M 62.84) [40]—particularly for the progressive increase in life expectancy, for its global diffusion, and for the strong association with several chronic diseases [41]. It is estimated that during the next 30 years, the prevalence of sarcopenia will significantly rise [42], making it a major public health issue.

Currently, increasing attention has been paid to sarcopenia in T2DM individuals, for both clinical and research reasons, due to the heavy impact that sarcopenia may have on the quality of life of elderly people with T2DM [43], in which frailty and sarcopenia are emerging as a third category of complications, in addition to the traditional microvascular and macrovascular disease leading to considerable disability [44].

Particular interest is focused around two issues: (1) whether sarcopenia is associated with features of the diabetic condition such as metabolic control, disease duration, and presence of diabetes complications, and (2) the role played by diet and glucose-lowering drugs in the development of sarcopenia. Information on these issues is relevant in order to better identify patients at higher risk for sarcopenia and to implement appropriate dietetic and pharmacological strategies to reduce this risk [45].

Against this background, the aim of the present narrative review is to provide an update on: (1) the risk of sarcopenia in individuals with T2DM and (2) its association with relevant features of T2DM patients such as age, gender, body mass index (BMI), disease duration, glycemic control, presence of microvascular or macrovascular complications, nutritional status, and glucose-lowering drugs.

2. Materials and Methods

We conducted a narrative review [46] by searching PubMed databases for articles published during the last 20 years (2000–2020), also considering, if available, previous most relevant studies, about the prevalence of sarcopenia in T2DM and its associated factors. The search dated from April 2020 to November 2020.

The medical subject heading (MeSH) terms “sarcopenia” AND “diabetes” OR “type 2 diabetes mellitus” OR “diabetes mellitus” OR “blood glucose control” OR “glycated hemoglobin” OR “diabetes treatment” OR “diabetes diet” OR “glucose-lowering drugs” OR “diabetes complications” OR “microvascular complications” OR “macrovascular complications” were utilized.

The search was limited to humans and the English language. With respect to article types, prospective cohort studies, retrospective and cross-sectional studies, meta-analyses, and systematic reviews on epidemiological studies were included in this narrative review. Furthermore, existing editorials and commentaries to the most relevant articles were also considered.

Conversely, studies that did not meet the selection criteria, duplicate publications, non-original articles, and studies in languages other than English were excluded. For the aim of our narrative review on prevalence/associated factors, we also excluded interventional clinical trials.

Titles and abstracts of retrieved studies were screened to select potentially relevant articles. Full texts were analyzed independently to determine whether they met the established inclusion criteria. Initially, 749 articles of potential interest were found. After screening of titles and abstracts, 56 papers were used for the aim of this narrative review.

3. Results

3.1. Prevalence of Sarcopenia in Individuals with Type 2 Diabetes Mellitus

In epidemiological studies, the prevalence of sarcopenia in T2DM has a wide range, varying from 7% to 29.3% in different populations [6,47–67], (Table 1).

Table 1. Prevalence of sarcopenia in patients with type 2 diabetes mellitus.

Reference	Study Design	Participants	BMI (Kg/m ²)	HbA1c (%)	Sarcopenia Assessment	Sarcopenia Prevalence
[47]	cross-sectional	144 M/W 71.4 years	23.9 ± 3.6	7.1 ± 0.7	AWGS	11.8%
[48]	cross-sectional	506 M/W 67.6 years	27.5 ± 8.1	8.1 ± 2.1	AWGS	28.5%
[49]	retrospective	238 M/W 67 years	24 ± 4.1	7.1 ± 1.3	AWGS	17.6%
[50]	cross-sectional	309 M/W 62.7 years	25.3 ± 2.9	6.7 ± 1.1	SMI	24.3%
[51]	cross-sectional	318 M/W 72.2 years	24.1 ± 4.4	7.3 ± 1.1	SARC-F	22.5%
[52]	cross-sectional	146 M/W 72.6 years	23.7 ± 3.6	7.1 ± 0.7	AWGS	14.4%
[53]	cross-sectional	391 M/W 72.4 years	23.8 ± 4.4	7.5 ± 1.4	AWGS	14.1%
[54]	cross-sectional	433 M/W 65.4 years	25.0 ± 4.7	7.6 ± 1.6	AWGS	7.4%
[55]	retrospective	312 M/W 64 years	24.7 ± 4.2	7.3 ± 1.4	AWGS	18%
[56]	cross-sectional	132 M/W 75.7 years	24.5 ± 3	7.8 ± 2.8	AWGS	28.8%
[57]	cross-sectional	746 M/W 69.9 years	24.7 ± 4.1	7.4 ± 1.3	AWGS	7%
[58]	cross-sectional	387 M/W 68.3 years	-	-	AWGS	27.4%
[59]	cross-sectional	166 M/W 63.2 years	26.3 ± 4.9	7.1 ± 1.1	AWGS	7.2%
[60]	cross-sectional	204 M/W 71.8 years	23.8 ± 4.0	7.2 ± 1.0	AWGS	8.8%
[61]	cross-sectional	183 M/W 64.7 years	25.3 ± 4.7	9.5 ± 2.1	AWGS	22%
[62]	cross-sectional	285 M/W 66.2 years	25.0 ± 4.6	7.1 ± 1.0	AWGS	8.8%
[63]	retrospective	716 M/W 65 years	24.7 ± 3.7	8.3 ± 1.9	AWGS	23.9%
[64]	cross-sectional	242 M/W 68.3 years	29.5 ± 4.5	7.8 ± 1.5	EWGSOP	21%
[65]	cross-sectional	250 M/W 71.7 years	25.3 ± 4.8	7.4 ± 1.0	SARC-F	19.5%
[66]	cross-sectional	267 M/W 73.7 years	24.0 ± 3.3	7.0 ± 1.0	AWGS	18.9%
[6]	cross-sectional	198 M/W 64.9 years	33.7 ± 7.7	8.1 ± 2.0	SARC-F	29.3%
[67]	cross-sectional	288 M/W 73.3 years	23.9 ± 3.5	7.6 ± 1.1	AWGS	15.2%

BMI: body mass index; HbA1c: glycated hemoglobin A1c; M: men; W: women; AWGS: Asian Working Group for Sarcopenia; SMI: skeletal muscle index; SARC-F: sluggishness, assistance in walking, rising from a chair, climb stairs, falls; -: data not available; EWGSOP: European Working Group on Sarcopenia in Older People.

In T2DM, a higher prevalence of sarcopenia has been consistently reported in respect to normoglycemic individuals. In particular, a very recent meta-analysis, including a total number of 6526 participants (1832 with T2DM and 4694 controls, and 1159 cases of sarcopenia), showed that the prevalence of sarcopenia is significantly higher in T2DM than in non-diabetic individuals (OR 1.55; 95% CI 1.25–1.91; $p < 0.001$) [68]. The prevalence of sarcopenia ranged from 5% to 50% in the 15 studies analyzed (seven studies were cross-sectional and eight were case-control, respectively). Interestingly, T2DM individuals presented lower muscle performance and strength compared with the normoglycemic ones, whereas no difference in muscle mass was observed [68]. Similarly, Veronese et al. in their meta-analysis reported that the prevalence of sarcopenia in T2DM was 28.4% vs. 18.7% in the control group (OR 1.63; 95% CI 1.20–2.22; $p = 0.002$) [69].

3.2. Sarcopenia in Individuals with Type 2 Diabetes Mellitus: Associated Factors

3.2.1. Age

A significant association between sarcopenia and age in T2DM individuals has been repeatedly reported. Most of the studies have shown that individuals with T2DM and sarcopenia on the average are older than those without sarcopenia: 73.6 years and 67.2 years, respectively (Figure 1A). In fact, as observed by Cui et al., the prevalence of sarcopenia in T2DM rises progressively by increasing age (17.4% in the age group 65–69 years, 28.1% in the age groups 70–74 years, 52.4% in the age groups 75–80 years, and 60% in the age groups above 80 years) [56]. Similarly, Murata et al. showed that approximately 40% of T2DM patients ≥ 80 years old present with sarcopenia [67].




Figure 1. Mean values of age (A) and body mass index (B) in type 2 diabetes mellitus individuals with and without sarcopenia in epidemiological studies. * $p < 0.05$; ** $p < 0.001$.

3.2.2. Gender

The impact of gender on the prevalence of sarcopenia differs among studies and data are not univocal. In some studies, a significantly higher prevalence of sarcopenia in men [48,63,64] or women [65,70] was reported. However, other studies [47,49–54,56–62,66] did not find any difference in gender distribution among T2DM with sarcopenia.

Furthermore, Anagnostis et al. reported that the point estimate for sarcopenia risk in men and women with T2DM was 1.72 (95% CI 1.1–2.69; $p = 0.017$) and 1.46 (95% CI 0.94–2.25; $p = 0.08$), respectively, compared with those without T2DM, and this difference between genders was not significant [68].

3.2.3. Body Mass Index

BMI is significantly lower in T2DM individuals with sarcopenia compared with those without it and many studies have shown that the prevalence of sarcopenia significantly decreases as BMI increases (Figure 1B). Interestingly, Fukuoka et al. showed that grouping T2DM individuals in quartiles of body fat, the lowest prevalence of sarcopenia was observed in the third quartile as compared with both the first and the fourth quartiles [66]. This finding suggests that in T2DM individuals, both a low BMI and high body fat are associated with sarcopenia.

3.2.4. Diabetes Duration

Looking at T2DM duration, data are not univocal. In some studies, the longer the duration of diabetes, the higher the prevalence of sarcopenia [47,53,54,59,66]. In particular, the paper by Cui et al. showed that dividing participants according to diabetes duration, the prevalence of sarcopenia was 27.6%, 21.8%, and 52.6%, respectively in the groups with a diabetes duration below 10, between 10 and 20, and above 20 years [65]. However, other studies [49,52,56,57,60,65] did not find any association between disease duration and sarcopenia (Figure 2A). This was confirmed by the meta-analysis of Anagnostis et al. showing no difference in sarcopenia prevalence between individuals with a mean T2DM duration of ≥ 9 years or < 8.5 years [68].

3.2.5. Glycemic Control

In epidemiological studies, glucose control, evaluated mainly by measuring glycated hemoglobin (HbA1c), has not been found associated with sarcopenia in T2DM individuals (Figure 2B). Only in few studies the frequency of sarcopenia was related to HbA1c levels [57,71]. Among them, Sugimoto et al. reported that the frequency of sarcopenia increases linearly with HbA1c, particularly in lean individuals, and this association is independent of major covariates, including anthropometric factors and duration of diabetes [57]. Contrarily, Ida et al. reported lower HbA1c levels in men with sarcopenia [60].


3.2.6. Microvascular and Macrovascular Complications

Retinopathy, nephropathy, and neuropathy are common microvascular complications of T2DM. In some studies, a difference in the prevalence of sarcopenia according to the presence of these complications has been observed. Fukuda et al. reported that sarcopenia and low muscle strength were significantly associated with the progression of diabetic retinopathy, and in particular, proliferative retinopathy (OR 7.78, 95% CI 1.52–39.81, $p = 0.014$, and OR 6.25, 95% CI 1.15–33.96, $p = 0.034$, respectively) [63].

Although the frequency of nephropathy was similar in T2DM individuals with and without sarcopenia [49,57,65,71], Bouchi et al. showed that in the presence of sarcopenia the risk for progression of albuminuria was increased [49].

With respect to neuropathy, Ida et al. reported that it was more frequent among women than among men in the sarcopenic group [51]. Nomura et al. reported that in men and women aged > 50 years, individuals with neuropathy had lower knee extension strength relative to body weight compared with individuals without neuropathy [72]; similar findings were reported by Kalyani et al. [73].

A



B




Figure 2. Mean values of diabetes duration (A) and glycated hemoglobin (B) in type 2 diabetes mellitus individuals with and without sarcopenia in epidemiological studies. * $p < 0.05$; ** $p < 0.001$; § $p < 0.05$ in men.

Epidemiological studies have not shown differences in the prevalence of cardiovascular diseases in T2DM patients with or without sarcopenia (Figure 3). In one study, Ida et al. observed a higher prevalence of cardiovascular disease in T2DM women with sarcopenia [51]. Interestingly, the paper by Murai et al. showed that in T2DM individuals with sarcopenia, lower muscle quality and high visceral fat were significantly associated with cardiovascular diseases as compared to the presence of lower muscle quality and low visceral fat; this suggests that T2DM individuals with visceral fat accumulation and low muscle quality have a higher cardiovascular risk [61].




Figure 3. Prevalence of cardiovascular diseases in type 2 diabetes mellitus individuals with and without sarcopenia in epidemiological studies. * $p < 0.05$ in people with high visceral fat; ** $p < 0.001$ in women.

With respect to diabetic foot disease, a common long-term complication of diabetes, Cheng et al. reported that the percentage of sarcopenia in diabetic foot disease patients was more than double than those without diabetic foot disease, and sarcopenia was independently associated with this condition [74]. Furthermore, in the diabetic foot disease group, patients with sarcopenia exhibited more foot ulcers, higher Wagner grade, and greater percentage of amputation compared with patients without sarcopenia [74].

3.2.7. Nutritional Status and Lifestyle

A high prevalence of sarcopenia in T2DM individuals with a poor nutritional status has been observed [75].

In particular, Okamura et al. reported that in T2DM patients with sarcopenia the energy intake was significantly lower than in those without sarcopenia (1499 vs. 1786 kcal/day, respectively), whereas no difference in the intake of proteins, carbohydrates, or fats was observed. After adjusting for age, sex, exercise, smoking status, HbA1c, and BMI, patient's energy intake was negatively associated with the presence of sarcopenia (OR 0.86; 95% CI 0.78–0.95; $p = 0.001$) [53].

In T2DM individuals with sarcopenia, the omega-3 fatty acids intake has been found to be reduced in comparison with those without sarcopenia (2.6 vs. 3.0 g/day, respectively) [76].

Regarding other lifestyle factors, epidemiological studies do not report differences in smoking and drinking habits between T2DM individuals with and without sarcopenia (Table 2), also when the analysis was performed separately in men and women [51,60]. Conversely, in T2DM individuals with sarcopenia the prevalence of physical activity has been found to be lower [56,64,77]; similarly, walking >5401 steps/day has been shown to have a protective effect since it is associated with a 70% lower prevalence of sarcopenia in T2DM patients [64].

Table 2. Prevalence of lifestyle habits in type 2 diabetes mellitus individuals with and without sarcopenia.

Reference	Smoking		Physical Activity		Habitual Alcohol Consumption	
	With Sarcopenia	Without Sarcopenia	With Sarcopenia	Without Sarcopenia	With Sarcopenia	Without Sarcopenia
[47]	5.8%	16.5%	58%	48.8%	-	-
[52]	42.8%	14.4%	57.1%	50.4%	-	-
[53]	3.6%	4.5%	12.7%	17.5%	-	-
[54]	12.5%	14.7%	6.3%	10.5%	-	-
[56]	26.3%	25.5%	52.6%	69.1%	15.7%	2.8%
[57]	-	-	42%	55%	-	-
[64]	0%	7%	-	-	46%	39%
[65]	18.4%	20.8%	-	-	13.5%	24.5%
[77]	26.3%	29.1%	37.8%	47.5%*	10.3%	15.6%

* $p < 0.05$. -: data not available; T2DM: type 2 diabetes mellitus.

3.2.8. Glucose-Lowering Drugs

In most studies evaluating the association between different glucose-lowering drugs and the prevalence of sarcopenia the majority of the participants were on at least two medications; the most frequently used were biguanides (metformin), dipeptidyl dipeptidase 4 inhibitors, sulfonylureas, and insulin (Table 3). Overall, the use of glucose-lowering drugs did not differ significantly between patients with or without sarcopenia, except for biguanides that were less frequently used in patients with sarcopenia [49,56,66,77]. Considering possible gender differences, the inverse association between biguanide use and sarcopenia was more marked in men [66].

Table 3. Glucose-lowering drug utilization in type 2 diabetes mellitus individuals with and without sarcopenia.

Reference	Metformin		TZDs		DPP-4 Inhibitors		Sulphonylureas		SGLT-2 Inhibitors		GLP-1 Analogues		Insulin	
	With Sarcopenia	Without Sarcopenia	With Sarcopenia	Without Sarcopenia	With Sarcopenia	Without Sarcopenia	With Sarcopenia	Without Sarcopenia	With Sarcopenia	Without Sarcopenia	With Sarcopenia	Without Sarcopenia	With Sarcopenia	Without Sarcopenia
[49]	19%	54% *	7%	10%	52%	60%	33%	24%	0%	3%	0%	5%	31%	24%
[52]	19%	38.4%	0%	5.6%	66.6%	48%	47.6%	35.2%	0%	12%	-	-	28.6%	14.4%
[56]	13.2%	42.5% *	-	-	-	-	-	-	-	-	-	-	68.4%	74.5%
[57]	25%	37.8%	11.5%	15%	59.6%	60.2%	17.3%	27.5%	5.8%	13.8%	5.8%	5.2%	59.6%	71.8%
[65]	-	-	-	-	-	-	-	-	-	-	12.2%	8.9%	79.5%	62.1% *
[66]	6%	24.4% *	6%	7.3%	52%	48.8%	20%	27.1%	0%	0.9%	1.5%	1.4%	24%	34.6%
[77]	48.6%	57.6% *	11.1%	12.8%	1%	0%	-	-	-	-	-	-	28.7%	24.8%

* $p < 0.05$. TZDs: thiazolidinediones; DPP-4: dipeptidyl peptidase 4; SGLT-2: sodium-glucose cotransporters; GLP-1: glucagon-like peptide-1; -: data not available.

4. Discussion

The evidence presented in this narrative review shows that the prevalence of sarcopenia in individuals with T2DM is high and widely ranges from 7% to 29.3%. The wide variation in sarcopenia prevalence could be due to different reasons such as the diagnostic criteria to assess it (muscle strength, muscle quantity/quality, and physical performance), as well as the different methods for its quantitative evaluation (dual-energy X-ray absorptiometry or bio-electrical impedance analysis). Moreover, the prevalence of sarcopenia in T2DM individuals may depend on the characteristics of the population such as ethnicity—most of the studies were carried out in Asia—age, BMI, or associated comorbidities.

The higher prevalence of sarcopenia in T2DM individuals may be explained by different mechanisms. The anabolic action of insulin in skeletal muscle is well known; it may be progressively lost in T2DM due to the impaired insulin sensitivity associated with this disease. In addition, the impairment in insulin action may induce a decreased protein synthesis and an increased protein degradation leading to a reduction in muscle mass and strength [78].

Furthermore, chronic hyperglycemia promotes per se the accumulation of advanced glycosylation end products (AGEs) in skeletal muscle, and a correlation between AGEs and reduction in grip strength, leg extension power, and slow walking speed has been reported [79]. Again, diabetes is associated with an increase in some inflammatory cytokines that may act on muscle loss and favor a reduction in muscle strength and function [45].

Finally, the higher prevalence of sarcopenia in T2DM is also related to the presence of macrovascular or microvascular complications, i.e., retinopathy, nephropathy, and neuropathy. In particular, chronic kidney disease secondary to diabetic nephropathy may affect muscle mass [80], peripheral diabetic neuropathy may impair its strength [72], together to a reduced physical activity and performance due to unstable postural balance or impaired vision [81]. Macrovascular complications, i.e., peripheral vascular disease, may also contribute by inducing muscle ischemia, as well as lower muscle strength, mass, and performance [82].

A significant association between sarcopenia and age in T2DM individuals has been repeatedly reported. It is not surprising that increasing age represents a risk factor for sarcopenia in T2DM, as well as in the general population, due to the age-related decline in skeletal muscle mass and strength as well as in physical performances.

It would be interesting to understand if the factor of age could be more determinant to sarcopenia development in individuals with T2DM compared with those without T2DM. In this regard, Tamura et al. showed no difference on sarcopenia risk according to age categories between individuals with and without T2DM [83]. Similarly, Çeliker et al. reported a higher prevalence of sarcopenia in T2DM individuals (21.4%) compared with those without T2DM (15.1%), while no significant differences in terms of age were observed [71]. Again, Trierweiler et al. reported a higher prevalence of sarcopenia in T2DM individuals (15.6%) compared with those without T2DM (2.4%), with a similar age between groups [84]. Interestingly, the meta-regression analysis (using as moderators mean age and the difference in mean age between individuals with T2DM and controls) performed by Veronese et al.—ten studies were included, showing an increased prevalence of sarcopenia in DT2M compared with controls—did not explain any of the differences found in the sarcopenia prevalence between groups with regard to age [69].

The impact of gender on sarcopenia prevalence in T2DM differs among studies, similarly to the general population, in which some studies showed a higher prevalence among men [85,86], whereas others depicted a higher prevalence among women [87,88]. With regard to sarcopenic obesity, a higher prevalence in men than in women was observed [38,89,90], probably related to the muscle decline in men and a fat increase in women during aging [90], as well as to hormonal changes [36]. Interestingly, women with sarcopenic obesity were more likely to have higher blood glucose, whereas men were more likely to have osteoporosis and dyslipidaemia [90].

BMI is significantly lower in T2DM individuals with sarcopenia compared with those without it. Notably, it is important to underline that individuals with T2DM and sarcopenia have normal weight (Figure 1B), despite the rising increase in obesity in T2DM. This surprising data could be related to the fact that most of the studies were carried out in Asia. Generally, Asians tend to have a relative lower BMI, a higher fat mass, and a lower prevalence of sarcopenic obesity than Caucasians [91,92]. Similarly, Asians with T2DM had lower BMI compared with Caucasians [93]. Furthermore, an increase in abdominal fat can be observed with aging, and this phenomenon might occur even without significant changes in BMI or body weight [94].

Therefore, an evaluation of obesity in elderly T2DM with sarcopenia should not be judged by BMI alone; rather, it should be considered in combination with other adiposity indices—i.e., waist circumference—or evaluation of body fat content [95].

Looking at T2DM duration, data are not univocal. The higher prevalence of sarcopenia observed in T2DM individuals with a longer duration of diabetes reported in some studies could be explained by the effect of chronic hyperglycemia on muscle mass/quality [96] or by the increased prevalence of diabetes complications associated with a longer disease duration [45,97].

In epidemiological studies, glucose control, evaluated mainly by HbA1c, has not been found associated with sarcopenia in T2DM individuals. It is important to underline that although some studies have reported that HbA1c levels are not associated with impaired muscle quality [98], muscle strength [99], and physical performance [73], a relationship between glucose control and sarcopenia cannot be completely excluded; in fact, HbA1c levels do not adequately reflect all the aspects of the day-to-day blood glucose profile and, in particular, the occurrence of hypoglycaemic episodes and the daily glucose fluctuations that may potentially represent risk factors for sarcopenia [100].

In relation to diabetes complications, there are some indications that sarcopenia could be associated with diabetic retinopathy, neuropathy, and foot disease. This last condition might further impair the quality of life of these patients, as well as increase the social and economic burden, cognitive impairment, gait disorder, depression, and morbidity [101,102]. Drammatically, sarcopenia increases the risk of mortality in patients who undergo amputation for a diabetic foot [103].

Looking at the nutritional aspects, it is widely known that malnutrition is one of the risk factors for the development of sarcopenia [12,104]. In the studies reviewed above, the intake of energy and omega-3 fatty acids are significantly reduced in T2DM patients with sarcopenia in comparison with those without this condition. It has been reported that a reduced energy intake, even with an appropriate supply of proteins, may cause a reduction in the protein synthesis in the human body [105]. With regard to omega-3 fatty acids, the explanation of this finding is not straightforward; however, it has been proposed that omega-3 fatty acids can reduce inflammation, thus improving the strength of skeletal muscle [106]. Moreover, they can stimulate muscle protein synthesis [107] and improve the overall neuromuscular function [108].

With regard to other dietary components, further aspects should be explored in T2DM with sarcopenia; in fact, in non-diabetic individuals, there are some promising data regarding the role of vitamin D and sarcopenia, but it is unclear whether the dose, frequency of dose, or length of treatment impacts the efficacy of vitamin D on improving muscle mass or function [109]. Furthermore, selenium and magnesium have been studied as supplements in clinical trials and in the diet, and they appear to demonstrate a potential association with physical activity, muscle performance, and bone health in older individuals [109,110]. Following the Mediterranean diet and higher consumption of fruits and vegetables have been associated with improved physical performance and protection against muscle wasting, sarcopenia, and frailty [109]. The supplementation of the branched-chain amino acid, leucine, or leucine-enriched protein is one of the most common interventions for treating sarcopenia in older individuals [111,112], and evidence reported that administration of leucine or leucine-enriched proteins (range 1.2–6 g leucine/day) is well-tolerated and

significantly affects sarcopenia in elderly individuals, improving muscle strength, lean mass content, and walking speed although these effects depend on sarcopenia criteria and the patients' characteristics [113].

A further interesting aspect to explore should be the intake of coffee—the most consumed psycho-active substance in the world—on sarcopenia in T2DM patients. In fact, evidence has shown that higher consumption of coffee, both caffeinated and decaffeinated, was associated with a significant lower risk of T2DM [114]; in particular, the risk of T2DM decreased by 6% for each cup-per-day increase in coffee consumption [115]. Epidemiological data from the Korea National Health and Nutrition Examination Survey suggested that consuming at least 3 cups of coffee per day was associated with a lower prevalence of sarcopenia [116], and Kim et al. reported that men who drink one cup of coffee per day were less prone to developing sarcopenia compared to those who rarely drink coffee [117]. The plausible protective role of coffee on sarcopenia might be related to its components with anti-inflammatory and antioxidant properties [118].

Regarding lifestyle factors, epidemiological studies reported that in T2DM individuals with sarcopenia, the prevalence of physical activity is lower. It is important to underline that the kind and the level of physical activity was variable among the studies and defined as: to perform any kind of sport regularly at least once a week [47,52–54], to count number of steps/day [56,57], to perform 150 min/week of moderate-intensity aerobic physical activity (50–70% of maximum heart rate) [77].

Similarly, also in individuals without T2DM, the prevalence of physical activity has been found to be lower. In the AGES–Reykjavik study, 53.8% of sarcopenic individuals did not engage in physical activity compared with 37.3% of non sarcopenic individual [119]; Kim et al. reported that only 24% of severely sarcopenic individuals engaged physical activity compared with 42.8% of non-sarcopenic individuals [120]. The beneficial effect of physical activity on sarcopenia might be related to the improvement in muscle mass, strength, and function [105].

As for the glucose lowering drugs, biguanides might have a protective role for the development of sarcopenia, as indicated by observational cross-sectional studies; however, data from prospective or intervention trials are lacking. The presumed protective role of metformin in relation to sarcopenia may be explained by some possible actions of this drug such as the effect on insulin sensitivity—involved in the uptake of glucose and calcium in skeletal muscles [121]—and the reduction of inflammation and oxidative stress, which may lead to an improvement of muscle quality and strength [122,123].

5. Conclusions

The available evidence is rather concordant in showing that the prevalence of sarcopenia in T2DM patients is increased. Different mechanisms may be responsible for this association such as impaired insulin sensitivity, chronic hyperglycemia, AGEs, subclinical inflammation, and microvascular and macrovascular complications. However, only increased age and a low BMI have been demonstrated to represent major risk factors for sarcopenia in T2DM. Information on other features of T2DM associated with this condition are inconsistent; nevertheless, overall, glucose control and diabetes duration do not seem to play a major role. In relation to diabetes complications, there are some indications that sarcopenia could be associated with diabetic retinopathy, neuropathy, and foot disease, while no association with macrovascular complications has been observed.

Among the lifestyle factors, the intake of energy and omega-3 fatty acids as well as the habitual physical activity are significantly reduced in T2DM patients with sarcopenia in comparison with those without this condition. As for the glucose-lowering drugs, biguanides might have a protective role for the development of sarcopenia, as indicated by observational cross-sectional studies; however, data from prospective or intervention trials are lacking.

In conclusion, the increased prevalence of sarcopenia in the elderly population with T2DM and its heavy impact on their quality of life, affecting physical and psychosocial

health, make it a major public health issue. Major research gaps in this issue include the relationship of sarcopenia with relevant features of T2DM and its treatment as well as the possibility to prevent it by appropriate lifestyle interventions. From a clinical point of view, it is of paramount importance to increase the ability of physicians and nutritionists to recognize the presence of sarcopenia and its risk factors in T2DM, particularly in older patients with a low BMI; this would allow the implementation of appropriate therapeutical strategies focused on adequate energy intake and regular physical activity. On the other hand, a more effective—although not at all easy—approach to reduce the prevalence and the severity of sarcopenia in the elderly population would be the implementation of lifestyle modifications known to be effective in the prevention of T2DM.

Author Contributions: G.D.P. and G.R. conceptualized the manuscript. A.I., E.M. and G.D.P. conducted literature research. G.D.P. wrote the draft of the review. A.I. drafted the sections regarding age, body mass index, diabetes duration, and glycemic control. E.M. drafted the section regarding nutritional status and glucose-lowering drugs. G.R. provided relevant intellectual contribution to the development of the review. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res. Clin. Pract.* **2019**, *157*, 107843. [[CrossRef](#)]
2. Umegaki, H. Sarcopenia and frailty in older patients with diabetes mellitus. *Geriatr. Gerontol. Int.* **2016**, *16*, 293–299. [[CrossRef](#)]
3. Ogurtsova, K.; da Rocha Fernandes, J.; Huang, Y.; Linnenkamp, U.; Guariguata, L.; Cho, N.H.; Cavan, D.; Shaw, J.; Marakoff, L. IDF diabetes atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. *Diabetes Res. Clin. Pract.* **2017**, *128*, 40–50. [[CrossRef](#)] [[PubMed](#)]
4. American Diabetes Association. 12. Older adults: Standards of Medical Care in Diabetes-2019. *Diabetes Care* **2019**, *42*, S139–S147. [[CrossRef](#)] [[PubMed](#)]
5. Kirkman, M.S.; Briscoe, V.S.; Clark, N.; Florez, H.; Haas, L.B.; Halter, J.B.; Huang, E.S.; Korytkowski, M.T.; Munshi, M.N.; Odegaard, P.S.; et al. Diabetes in older adults. *Diabetes Care* **2012**, *35*, 2650–2664. [[CrossRef](#)]
6. Liccini, A.; Malmstrom, T.K. Frailty and Sarcopenia as Predictors of Adverse Health Outcomes in Persons with Diabetes Mellitus. *J. Am. Med. Dir. Assoc.* **2016**, *17*, 846–851. [[CrossRef](#)] [[PubMed](#)]
7. Rosenberg, I.H. Sarcopenia: Origins and clinical relevance. *J. Nutr.* **1997**, *127*, 990S–991S. [[CrossRef](#)]
8. Baumgartner, R.N.; Koehler, K.M.; Gallagher, D.; Romero, L.; Heymsfield, S.B.; Ross, R.R.; Garry, P.J.; Lindeman, R.D. Epidemiology of sarcopenia among the elderly in New Mexico. *Am. J. Epidemiol.* **1998**, *147*, 755–763. [[CrossRef](#)]
9. Filippin, L.I.; Teixeira, V.N.; da Silva, M.P.; Miraglia, F.; da Silva, F.S. Sarcopenia: A predictor of mortality and the need for early diagnosis and intervention. *Aging Clin. Exp. Res.* **2015**, *27*, 249–254. [[CrossRef](#)]
10. Goodpaster, B.H.; Park, S.W.; Harris, T.B.; Kritchevsky, S.B.; Nevitt, M.; Schwartz, A.V.; Simonsick, E.M.; Tylavsky, F.A.; Visser, M.; Newman, A.B. The loss of skeletal muscle strength, mass, and quality in older adults: The health, aging and body composition study. *J. Gerontol. A Biol. Sci. Med. Sci.* **2006**, *61*, 1059–1064. [[CrossRef](#)]
11. Cruz-Jentoft, A.J.; Baeyens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.P.; Rolland, Y.; Schneider, S.M.; et al. European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing* **2010**, *39*, 412–423. [[CrossRef](#)] [[PubMed](#)]
12. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2); and the Extended Group for EWGSOP2. Sarcopenia: Revised European consensus on definition and diagnosis. *Age Ageing* **2019**, *48*, 16–31. [[CrossRef](#)] [[PubMed](#)]
13. Chen, L.K.; Liu, L.K.; Woo, J.; Assantachai, P.; Auyeung, T.W.; Bahyah, K.S.; Chou, M.Y.; Chen, L.Y.; Hsu, P.S.; Krairit, O.; et al. Sarcopenia in Asia: Consensus report of the Asian Working Group for Sarcopenia. *J. Am. Med. Dir. Assoc.* **2014**, *15*, 95–101. [[CrossRef](#)]
14. Fielding, R.A.; Vellas, B.; Evans, W.J.; Bhasin, S.; Morley, J.E.; Newman, A.B.; van Kan Abellan, G.; Andrieu, S.; Bauer, J.; Breuille, D.; et al. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International working group on sarcopenia. *J. Am. Med. Dir. Assoc.* **2011**, *12*, 249–256. [[CrossRef](#)]

15. Studenski, S.A.; Peters, K.W.; Alley, D.E.; Cawthon, P.M.; McLean, R.R.; Harris, T.B.; Ferrucci, L.; Guralnik, J.M.; Fragala, M.S.; Kenny, A.M.; et al. The FNIH sarcopenia project: Rationale, study description, conference recommendations, and final estimates. *J. Gerontol. A Biol. Sci. Med. Sci.* **2014**, *69*, 547–558. [[CrossRef](#)]
16. Mayhew, A.J.; Amog, K.; Phillips, S.; Parise, G.; McNicholas, P.D.; de Souza, R.J.; Thabane, L.; Raina, P. The prevalence of sarcopenia in community-dwelling older adults, an exploration of differences between studies and within definitions: A systematic review and meta-analyses. *Age Ageing* **2019**, *48*, 48–56. [[CrossRef](#)]
17. Shafiee, G.; Keshtkar, A.; Soltani, A.; Ahadi, Z.; Larijani, B.; Heshmat, R. Prevalence of sarcopenia in the world: A systematic review and meta-analysis of general population studies. *J. Diabetes Metab. Disord.* **2017**, *16*, 16–21. [[CrossRef](#)]
18. Reijnierse, E.M.; Buljan, A.; Tuttle, C.S.L.; Ancum, J.V.; Verlaan, S.; Meskers, C.G.M.; Maier, A.B. Prevalence of sarcopenia in inpatients 70 years and older using different diagnostic criteria. *Nurs. Open* **2018**, *6*, 377–383. [[CrossRef](#)]
19. Churilov, I.; Churilov, L.; MacIsaac, R.J.; Ekinc, E.I. Systematic review and meta-analysis of prevalence of sarcopenia in post acute inpatient rehabilitation. *Osteoporos. Int.* **2018**, *29*, 805–812. [[CrossRef](#)]
20. Chang, K.V.; Hsu, T.H.; Wu, W.T.; Huang, K.C.; Han, D.S. Association between Sarcopenia and Cognitive Impairment: A Systematic Review and Meta-Analysis. *J. Am. Med. Dir. Assoc.* **2016**, *17*, 1164.e7–1164.e15. [[CrossRef](#)]
21. Beaudart, C.; Zaaria, M.; Pasleau, F.; Reginster, J.Y.; Bruyère, O. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis. *PLoS ONE* **2017**, *12*, e0169548. [[CrossRef](#)]
22. Chang, K.V.; Hsu, T.H.; Wu, W.T.; Huang, K.C.; Han, D.S. Is sarcopenia associated with depression? A systematic review and meta-analysis of observational studies. *Age Ageing* **2017**, *46*, 738–746. [[CrossRef](#)]
23. Yeung, S.S.Y.; Reijnierse, E.M.; Pham, V.K.; Trappenburg, M.C.; Lim, W.K.; Meskers, C.G.M.; Maier, A.B. Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis. *J. Cachexia Sarcopenia Muscle* **2019**, *10*, 485–500. [[CrossRef](#)]
24. Keevil, V.L.; Romero-Ortuno, R. Ageing well: A review of sarcopenia and frailty. *Proc. Nutr. Soc.* **2015**, *74*, 337–347. [[CrossRef](#)]
25. Satake, S.; Arai, H. Frailty: Definition, diagnosis, epidemiology. *Geriatr. Gerontol. Int.* **2020**, *20*, 7–13. [[CrossRef](#)]
26. Kojima, G.; Liljas, A.; Iliffe, S. Frailty syndrome: Implications and challenges for health care policy. *Risk Manag. Healthc. Policy* **2019**, *12*, 23–30. [[CrossRef](#)]
27. Fried, L.P.; Tangen, C.M.; Walston, J.; Newman, A.B.; Hirsch, C.; Gottdiener, J.; Seeman, T.; Tracy, R.; Kop, W.J.; Burke, G.; et al. Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: Evidence for a phenotype. *J. Gerontol. A Biol. Sci. Med. Sci.* **2001**, *56*, 146–156. [[CrossRef](#)]
28. Buta, B.J.; Walston, J.D.; Godino, J.G.; Park, M.; Kalyani, R.R.; Xue, Q.L.; Bandeen-Roche, K.; Varadhan, R. Frailty assessment instruments: Systematic characterization of the uses and contexts of highly-cited instruments. *Ageing Res. Rev.* **2016**, *26*, 53–61. [[CrossRef](#)]
29. Rolfson, D.B.; Majumdar, S.R.; Tsuyuki, R.T.; Tahir, A.; Rockwood, K. Validity and reliability of the Edmonton Frail Scale. *Age Ageing* **2006**, *35*, 526–529. [[CrossRef](#)]
30. Navarro-Flores, E.; de Bengoa Vallejo, R.B.; Losa-Iglesias, M.E.; Palomo-López, P.; Calvo-Lobo, C.; López-López, D.; Martínez-Jiménez, E.M.; Romero-Morales, C. The reliability, validity, and sensitivity of the Edmonton Frail Scale (EFS) in older adults with foot disorders. *Ageing* **2020**, *12*, 10. [[CrossRef](#)]
31. Navarro-Flores, E.; Romero-Morales, C.; Becerro de Bengoa-Vallejo, R.; Rodríguez-Sanz, D.; Palomo-López, P.; López-López, D.; Losa-Iglesias, M.E.; Calvo-Lobo, C. Sex Differences in Frail Older Adults with Foot Pain in a Spanish Population: An Observational Study. *Int. J. Environ. Res. Public Health* **2020**, *17*, 6141. [[CrossRef](#)]
32. Morley, J.E.; Malmstrom, T.K.; Miller, D.K. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. *J. Nutr. Health Aging* **2012**, *16*, 601–608. [[CrossRef](#)]
33. Rolfson, D.B.; Majumdar, S.R.; Tahir, A.S.; Tsuyuki, R.T. Content validation of a frailty checklist derived from comprehensive geriatric assessment. *Gerontology* **2001**, *47*, 119.
34. Moraes, E.N.; Carmo, J.A.; Moraes, F.L.; Azevedo, R.S.; Machado, C.J.; Montilla, D.E.R. Clinical-Functional Vulnerability Index-20 (IVCF-20): Rapid recognition of frail older adults. *Rev. Saude Publica* **2016**, *50*, 81. [[CrossRef](#)]
35. Nezameddin, R.; Itani, L.; Kreidieh, D.; El Masri, D.; Tannir, H.; El Ghoch, M. Understanding Sarcopenic Obesity in Terms of Definition and Health Consequences: A Clinical Review. *Curr. Diabetes Rev.* **2020**, *16*, 957–961. [[CrossRef](#)]
36. Wang, M.; Tan, Y.; Shi, Y.; Wang, X.; Liao, Z.; Wei, P. Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments. *Front. Endocrinol.* **2020**, *11*, 568. [[CrossRef](#)]
37. Baek, S.J.; Nam, G.E.; Han, K.D.; Choi, S.W.; Jung, S.W.; Bok, A.R.; Kim, Y.H.; Lee, K.S.; Han, B.D.; Kim, D.H. Sarcopenia and sarcopenic obesity and their association with dyslipidemia in Korean elderly men: The 2008–2010 Korea National Health and Nutrition Examination Survey. *J. Endocrinol. Investig.* **2014**, *37*, 247–260. [[CrossRef](#)]
38. Kim, T.N.; Yang, S.J.; Yoo, H.J.; Lim, K.I.; Kang, H.J.; Song, W.; Seo, J.A.; Kim, S.G.; Kim, N.H.; Baik, S.H.; et al. Prevalence of sarcopenia and sarcopenic obesity in Korean adults: The Korean sarcopenic obesity study. *Int. J. Obes.* **2009**, *33*, 885–892. [[CrossRef](#)]
39. Kim, J.H.; Cho, J.J.; Park, Y.S. Relationship between sarcopenic obesity and cardiovascular disease risk as estimated by the Framingham risk score. *J. Korean Med. Sci.* **2015**, *30*, 264–271. [[CrossRef](#)]
40. Cao, L.; Morley, L.E. Sarcopenia Is Recognized as an Independent Condition by an International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) Code. *J. Am. Med. Dir. Assoc.* **2016**, *17*, 675–677. [[CrossRef](#)]

41. Pacifico, J.; Geerlings, M.A.J.; Reijnierse, E.M.; Phassouliotis, C.; Lim, W.K.; Maier, A.B. Prevalence of sarcopenia as a comorbid disease: A systematic review and meta-analysis. *Exp. Gerontol.* **2020**, *131*, 110801. [[CrossRef](#)]
42. Ethgen, O.; Beaudart, C.; Buckinx, F.; Bruyère, O.; Reginster, J.Y. The Future Prevalence of Sarcopenia in Europe: A Claim for Public Health Action. *Calcif. Tissue Int.* **2017**, *100*, 229–234. [[CrossRef](#)]
43. Wong, E.; Backholer, K.; Gearon, E.; Harding, J.; Freak-Poli, R.; Stevenson, C.; Peeters, A. Diabetes and risk of physical disability in adults: A systematic review and meta-analysis. *Lancet Diabetes Endocrinol.* **2013**, *1*, 106–114. [[CrossRef](#)]
44. Cobo, A.; Vázquez, L.A.; Reviriego, J.; Rodríguez-Manas, L. Impact of frailty in older patients with diabetes mellitus: An overview. *Endocrinol. Nutr.* **2016**, *63*, 291–303. [[CrossRef](#)]
45. Mesinovic, J.; Zengin, A.; De Courten, B.; Ebeling, P.R.; Scott, D. Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship. *Diabetes Metab. Syndr. Obes.* **2019**, *12*, 1057–1072. [[CrossRef](#)]
46. Baethge, C.; Goldbeck-Wood, S.; Mertens, S. SANRA-a scale for the quality assessment of narrative review articles. *Res. Integr. Peer Rev.* **2019**, *4*, 5. [[CrossRef](#)]
47. Kaji, A.; Hashimoto, Y.; Kobayashi, Y.; Sakai, R.; Okamura, T.; Miki, A.; Hamaguchi, M.; Kuwahata, M.; Yamazaki, M.; Fukui, M. Sarcopenia is associated with tongue pressure in older patients with type 2 diabetes: A cross-sectional study of the KAMOGAWA-DM cohort study. *Geriatr. Gerontol. Int.* **2019**, *19*, 153–158. [[CrossRef](#)]
48. Szalina, S.G.; Lee, P.Y.; Chan, Y.M.; A Hamid, M.S.; Tan, N.C. The prevalence and factors associated with sarcopenia among community living elderly with type 2 diabetes mellitus in primary care clinics in Malaysia. *PLoS ONE* **2020**, *15*, e0233299. [[CrossRef](#)]
49. Bouchi, R.; Fukuda, T.; Takeuchi, T.; Minami, I.; Yoshimoto, T.; Ogawa, Y. Sarcopenia is associated with incident albuminuria in patients with type 2 diabetes: A retrospective observational study. *J. Diabetes Investig.* **2017**, *8*, 783–787. [[CrossRef](#)]
50. Sung, M.J.; Lim, T.S.; Jeon, M.Y.; Lee, H.W.; Kim, B.K.; Kim, D.Y.; Ahn, S.H.; Han, K.; Park, J.Y.; Kim, S.U. Sarcopenia Is Independently Associated with the Degree of Liver Fibrosis in Patients with Type 2 Diabetes Mellitus. *Gut Liver* **2020**, *4*, 626–635. [[CrossRef](#)]
51. Ida, S.; Kaneko, R.; Nagata, H.; Noguchi, Y.; Araki, Y.; Nakai, M.; Ito, S.; Ishihara, Y.; Imataka, K.; Murata, K. Association between sarcopenia and sleep disorder in older patients with diabetes. *Geriatr. Gerontol. Int.* **2019**, *19*, 399–403. [[CrossRef](#)] [[PubMed](#)]
52. Hashimoto, Y.; Kaji, A.; Sakai, R.; Hamaguchi, M.; Okada, H.; Ushigome, E.; Asano, M.; Yamazaki, M.; Fukui, M. Sarcopenia is associated with blood pressure variability in older patients with type 2 diabetes: A cross-sectional study of the KAMOGAWA-DM cohort study. *Geriatr. Gerontol. Int.* **2018**, *18*, 1345–1349. [[CrossRef](#)] [[PubMed](#)]
53. Okamura, T.; Mik, A.; Hashimoto, Y.; Kaji, A.; Sakai, R.; Osaka, T.; Hamaguchi, M.; Yamazaki, M.; Fukui, M. Deficiency of energy intake rather than protein is associated with sarcopenia in early patients with type 2 diabetes: A cross-sectional study of the KAMOGAWA-DM cohort. *J. Diabetes* **2019**, *11*, 477–483. [[CrossRef](#)] [[PubMed](#)]
54. Okamura, T.; Hashimoto, Y.; Miki, A.; Kaji, A.; Sakai, R.; Iwai, K.; Osaka, T.; Kitagawa, N.; Ushigome, E.; Hamaguchi, M.; et al. High brain natriuretic peptide is associated with sarcopenia in patients with type 2 diabetes: A cross-sectional study of KAMOGAWA-DM cohort study. *Endocr. J.* **2019**, *66*, 369–377. [[CrossRef](#)]
55. Bouchi, R.; Fukuda, T.; Takeuchi, T.; Nakano, Y.; Murakami, M.; Minami, I.; Izumiyama, H.; Hashimoto, K.; Yoshimoto, T.; Ogawa, Y. Insulin Treatment Attenuates Decline of Muscle Mass in Japanese Patients with Type 2 Diabetes. *Calcif. Tissue Int.* **2017**, *101*, 1–8. [[CrossRef](#)]
56. Cui, M.; Gang, X.; Wang, G.; Xiao, X.; Li, Z.; Jiang, Z.; Wang, G. A cross-sectional study: Associations between sarcopenia and clinical characteristics of patients with type 2 diabetes. *Medicine* **2020**, *99*, e18708. [[CrossRef](#)]
57. Sugimoto, K.; Tabara, Y.; Ikegami, H.; Takata, Y.; Kamide, K.; Ikezoe, T.; Kiyoshige, E.; Makutani, Y.; Onuma, H.; Gondo, Y.; et al. Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: The Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus. *J. Diabetes Investig.* **2019**, *10*, 1471–1479. [[CrossRef](#)]
58. Fung, F.Y.; Koh, Y.L.E.; Malhotra, R.; Ostbye, T.; Lee, P.Y.; Ghazali, S.S.; Tan, N.C. Prevalence of and factors associated with sarcopenia among multi-ethnic ambulatory older Asians with type 2 diabetes mellitus in a primary care setting. *BMC Geriatr.* **2019**, *19*, 122. [[CrossRef](#)]
59. Mori, H.; Kuroda, A.; Ishizu, M.; Ohishi, M.; Takashi, Y.; Otsuka, Y.; Taniguchi, S.; Tamaki, M.; Kurahashi, K.; Yoshida, S.; et al. Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes. *J. Diabetes Investig.* **2019**, *10*, 1332–1340. [[CrossRef](#)]
60. Ida, S.; Murata, K.; Nakadachi, D.; Ishihara, Y.; Imataka, K.; Uchida, A.; Monguchi, K.; Kaneko, R.; Fujiwara, R.; Takahashi, H. Association between dynapenia and decline in higher-level functional capacity in older men with diabetes. *Geriatr. Gerontol. Int.* **2018**, *18*, 1393–1397. [[CrossRef](#)]
61. Murai, J.; Nishizawa, H.; Otsuka, A.; Fukuda, S.; Tanaka, Y.; Nagao, H.; Sakai, Y.; Suzuki, M.; Yokota, S.; Tada, H.; et al. Low muscle quality in Japanese type 2 diabetic patients with visceral fat accumulation. *Cardiovasc. Diabetol.* **2018**, *17*, 112. [[CrossRef](#)] [[PubMed](#)]
62. Osaka, T.; Hamaguchi, M.; Hashimoto, Y.; Ushigome, E.; Tanaka, M.; Yamazaki, M.; Fukui, M. Decreased the creatinine to cystatin C ratio is a surrogate marker of sarcopenia in patients with type 2 diabetes. *Diabetes Res. Clin. Pract.* **2018**, *139*, 52–58. [[CrossRef](#)] [[PubMed](#)]

63. Fukuda, T.; Bouchi, R.; Takeuchi, T.; Tsujimoto, K.; Minami, I.; Yoshimoto, T.; Ogawa, Y. Sarcopenic obesity assessed using dual energy X-ray absorptiometry (DXA) can predict cardiovascular disease in patients with type 2 diabetes: A retrospective observational study. *Cardiovasc. Diabetol.* **2018**, *17*, 55. [[CrossRef](#)] [[PubMed](#)]
64. de Freitas, M.M.; de Oliveira, V.L.P.; Grassi, T.; Valduga, K.; Miller, M.E.P.; Schuchmann, R.A.; Souza, K.L.A.; de Azevedo, M.J.; Viana, L.V.; de Paula, T.P. Difference in sarcopenia prevalence and associated factors according to 2010 and 2018 European consensus (EWGSOP) in elderly patients with type 2 diabetes mellitus. *Exp. Gerontol.* **2020**, *132*, 110835. [[CrossRef](#)] [[PubMed](#)]
65. Ida, S.; Nakai, M.; Ito, S.; Ishihara, Y.; Imataka, K.; Uchida, A.; Monguchi, K.; Kaneko, R.; Fujiwara, R.; Takahashi, H.; et al. Association Between Sarcopenia and Mild Cognitive Impairment Using the Japanese Version of the SARC-F in Elderly Patients With Diabetes. *J. Am. Med. Dir. Assoc.* **2017**, *18*, 809.e9–809.e13. [[CrossRef](#)] [[PubMed](#)]
66. Fukuoka, Y.; Narita, T.; Fujita, H.; Morii, T.; Sato, T.; Sassa, M.H.; Yamada, Y. Importance of physical evaluation using skeletal muscle mass index and body fat percentage to prevent sarcopenia in elderly Japanese diabetes patients. *J. Diabetes Investig.* **2019**, *10*, 322–330. [[CrossRef](#)] [[PubMed](#)]
67. Murata, Y.; Kadoya, Y.; Yamada, S.; Sank, T. Sarcopenia in elderly patients with type 2 diabetes mellitus: Prevalence and related clinical factors. *Diabetol. Int.* **2017**, *9*, 136–142. [[CrossRef](#)]
68. Anagnostis, P.; Gkekas, N.K.; Achilla, C.; Pananastasiou, G.; Taoukidou, P.; Mitsiou, M.; Kenanidis, E.; Potoupnis, M.; Tsiroidis, E.; Goulis, D.G. Type 2 Diabetes Mellitus Is Associated with Increased Risk of Sarcopenia: A Systematic Review and Meta-analysis. *Calcif. Tissue Int.* **2020**, *107*, 453–463. [[CrossRef](#)]
69. Veronese, N.; Stubbs, B.; Punzi, L.; Soysal, P.; Incalzi, R.A.; Saller, A.; Maggi, S. Effect of nutritional supplementations on physical performance and muscle strength parameters in older people. A systematic review and meta-analysis. *Ageing Res. Rev.* **2019**, *51*, 48–54. [[CrossRef](#)]
70. Chen, F.; Xu, S.; Wang, Y.; Chen, F.; Cao, L.; Liu, T.; Huang, T.; Wei, Q.; Ma, G.; Zhao, Y.; et al. Risk Factors for Sarcopenia in the Elderly with Type 2 Diabetes Mellitus and the Effect of Metformin. *J. Diabetes Res.* **2020**, *7*, 3950404. [[CrossRef](#)]
71. Çeliker, M.; Selçuk, M.Y.; Olt, S. Sarcopenia in diabetic nephropathy: A cross-sectional study. *Rom. J. Intern. Med.* **2018**, *56*, 102–108. [[CrossRef](#)] [[PubMed](#)]
72. Nomura, T.; Ishiguro, T.; Ohira, M.; Ikeda, Y. Diabetic polyneuropathy is a risk factor for decline of lower extremity strength in patients with type 2 diabetes. *J. Diabetes Investig.* **2018**, *9*, 186–192. [[CrossRef](#)] [[PubMed](#)]
73. Kalyani, R.R.; Metter, E.J.; Egan, J.; Golden, S.H.; Ferrucci, L. Hyperglycemia predicts persistently lower muscle strength with aging. *Diabetes Care* **2015**, *38*, 82–90. [[CrossRef](#)] [[PubMed](#)]
74. Cheng, Q.; Hu, J.; Yang, P.; Cao, X.; Deng, X.; Yang, Q.; Liu, Z.; Yang, S.; Goswami, R.; Wang, Y.; et al. Sarcopenia is independently associated with diabetic foot disease. *Sci. Rep.* **2017**, *7*, 8372. [[CrossRef](#)] [[PubMed](#)]
75. Velázquez-Alva, M.C.; Irigoyen-Camacho, M.E.; Zepeda-Zepeda, M.A.; Lazarevich, I.; Arrieta-Cruz, I.; D'Hyve, C. Sarcopenia, nutritional status and type 2 diabetes mellitus: A cross-sectional study in a group of Mexican women residing in a nursing home. *Nutr. Diet.* **2020**, *77*, 515–522. [[CrossRef](#)] [[PubMed](#)]
76. Okamura, T.; Hashimoto, Y.; Miki, A.; Kaji, A.; Sakai, R.; Iwai, K.; Osaka, T.; Kitagawa, N.; Ushigome, E.; Hamaguchi, M.; et al. Reduced dietary omega3 fatty acids intake is associated with sarcopenia in elderly patients with type 2 diabetes: A cross-sectional study of KAMOGAWA-DM cohort study. *J. Clin. Biochem. Nutr.* **2020**, *66*, 233–237. [[CrossRef](#)]
77. Yang, R.; Zhang, Y.; Shen, X.; Yan, S. Sarcopenia associated with renal function in the patients with type 2 diabetes. *Diabetes Res. Clin. Pract.* **2016**, *118*, 121–129. [[CrossRef](#)]
78. Pereira, S.; Marliss, E.B.; Morais, J.A.; Chevalier, S.; Gougeon, R. Insulin resistance of protein metabolism in type 2 diabetes. *Diabetes* **2008**, *57*, 56–63. [[CrossRef](#)]
79. Tabara, Y.; Ikezoe, T.; Yamanaka, M.; Setoh, K.; Segawa, H.; Kawaguchi, T.; Kosugi, S.; Nakayama, T.; Ichihashi, N.; Tsuboyama, T.; et al. Advanced Glycation End Product Accumulation Is Associated With Low Skeletal Muscle Mass, Weak Muscle Strength, and Reduced Bone Density: The Nagahama Study. *J. Gerontol. A Biol. Sci. Med. Sci.* **2019**, *74*, 1446–1453. [[CrossRef](#)]
80. Wang, X.H.; Mitc, W.E. Mechanisms of muscle wasting in chronic kidney disease. *Nat. Rev. Nephrol.* **2014**, *10*, 504–516. [[CrossRef](#)]
81. Gupta, P.; Aravindhan, A.; Gand, A.; Man, R.; Fenwick, E.K.; Mitchell, P.; Tan, N.; Sabanayagam, C.; Wong, T.Y.; Cheng, C.Y.; et al. Association Between the Severity of Diabetic Retinopathy and Falls in an Asian Population With Diabetes: The Singapore Epidemiology of Eye Diseases Study. *JAMA Ophthalmol.* **2017**, *135*, 1410–1416. [[CrossRef](#)] [[PubMed](#)]
82. Dziubek, W.; Bulińska, K.; Stefańska, M.; Woźniewski, M.; Kropielnicka, K.; Jasiński, T.; Jasiński, R.; Pilch, U.; Dąbrowska, G.; Skórkowska-Telichowska, K.; et al. Peripheral arterial disease decreases muscle torque and functional walking capacity in elderly. *Maturitas* **2015**, *81*, 480–486. [[CrossRef](#)] [[PubMed](#)]
83. Tamura, Y.; Ishikawa, J.; Fujiwara, Y.; Tanaka, M.; Kanazawa, N.; Chiba, Y.; Iizuka, A.; Kaito, S.; Tanaka, J.; Sugie, M.; et al. Prevalence of frailty, cognitive impairment, and sarcopenia in outpatients with cardiometabolic disease in a frailty clinic. *BMC Geriatr.* **2018**, *18*, 264. [[CrossRef](#)] [[PubMed](#)]
84. Trierweiler, H.; Kisielwicz, G.; Jonasson, T.H.; Petterle, R.R.; Moreira, C.A.; Borba, V.Z.C. Sarcopenia: A chronic complication of type 2 diabetes mellitus. *Diabetol. Metab. Syndr.* **2018**, *10*, 25. [[CrossRef](#)] [[PubMed](#)]
85. Hai, S.; Wang, H.; Cao, L.; Liu, P.; Zhou, J.; Yang, Y.; Dong, B. Association between sarcopenia with lifestyle and family function among community-dwelling Chinese aged 60 years and older. *BMC Geriatr.* **2017**, *17*, 187. [[CrossRef](#)]
86. Huang, C.Y.; Hwang, A.C.; Liu, L.K.; Lee, W.J.; Chen, L.Y.; Peng, L.N.; Lin, M.H.; Chen, L.K. Association of Dynapenia, Sarcopenia, and Cognitive Impairment Among Community-Dwelling Older Taiwanese. *Rejuvenation Res.* **2016**, *19*, 71–78. [[CrossRef](#)]

87. Han, P.; Kang, L.; Guo, Q.; Wang, J.; Zhang, W.; Shen, S.; Wang, X.; Dong, R.; Ma, Y.; Shi, Y.; et al. Prevalence and Factors Associated With Sarcopenia in Suburb-dwelling Older Chinese Using the Asian Working Group for Sarcopenia Definition. *J. Gerontol. A Biol. Sci. Med. Sci.* **2016**, *71*, 529–535. [[CrossRef](#)]
88. Gao, L.; Jiang, J.; Yang, M.; Hao, Q.; Luo, L.; Dong, B. Prevalence of Sarcopenia and Associated Factors in Chinese Community-Dwelling Elderly: Comparison Between Rural and Urban Areas. *J. Am. Med. Dir. Assoc.* **2015**, *16*, 1003.e1–1003.e6. [[CrossRef](#)]
89. Bouchard, D.R.; Dionne, I.J.; Brochu, M. Sarcopenic/obesity and physical capacity in older men and women: Data from the nutrition as a determinant of successful aging (NuAge)-the Quebec longitudinal study. *Obesity* **2009**, *17*, 2082–2088. [[CrossRef](#)]
90. Du, Y.; Wang, X.; Xie, H.; Zheng, S.; Wu, X.; Zhu, X.; Zhang, X.; Xue, S.; Li, H.; Hong, W.; et al. Sex differences in the prevalence and adverse outcomes of sarcopenia and sarcopenic obesity in community dwelling elderly in East China using the AWGS criteria. *BMC Endocr. Disord.* **2019**, *19*, 109. [[CrossRef](#)]
91. Deurenberg, P.; Deurenberg-Yap, M.; Guricci, S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. *Obes. Rev.* **2002**, *3*, 141–146. [[CrossRef](#)] [[PubMed](#)]
92. Roh, E.; Choi, K.M. Health Consequences of Sarcopenic Obesity: A Narrative Review. *Front. Endocrinol.* **2020**, *11*, 332. [[CrossRef](#)] [[PubMed](#)]
93. Bank, I.; Gijsberts, C.M.; Teng, T.K.; Benson, L.; Sim, D.; Yeo, P.; Ong, H.Y.; Jaufeerally, F.; Leong, G.; Ling, L.H.; et al. Prevalence and Clinical Significance of Diabetes in Asian Versus White Patients With Heart Failure. *JACC Heart Fail.* **2017**, *5*, 14–24. [[CrossRef](#)]
94. Buffa, R.; Floris, G.U.; Putzu, P.F.; Marini, E. Body composition variations in ageing. *Coll. Antropol.* **2011**, *35*, 259–265. [[PubMed](#)]
95. Zamboni, M.; Armellini, F.; Harris, T.; Turcato, E.; Micciolo, R.; Bergamo-Andreis, I.A.; Bosello, O. Effects of age on body fat distribution and cardiovascular risk factors in women. *Am. J. Clin. Nutr.* **1997**, *66*, 111–115. [[CrossRef](#)]
96. Volpato, S.; Bianchi, L.; Lauretani, F.; Lauretani, F.; Bandinelli, S.; Guralnik, J.M.; Zuliani, G.; Ferrucci, L. Role of muscle mass and muscle quality in the association between diabetes and gait speed. *Diabetes Care* **2012**, *35*, 1672–1679. [[CrossRef](#)]
97. Sinclair, A.J.; Abdelhafiz, A.H.; Rodríguez-Mañas, L. Frailty and sarcopenia—Newly emerging and high impact complications of diabetes. *J. Diabetes Complicat.* **2017**, *31*, 1465–1473. [[CrossRef](#)]
98. Yoon, J.W.; Ha, Y.C.; Kim, K.M.; Moon, J.H.; Choi, S.H.; Lim, S.; Park, Y.J.; Lim, J.Y.; Kim, K.W.; Park, K.S.; et al. Hyperglycaemia is associated with impaired muscle quality in older men with diabetes: The Korean longitudinal health and aging study. *Diabetes Metab. J.* **2016**, *40*, 140–146. [[CrossRef](#)]
99. Leenders, M.; Verdijk, L.B.; van der Hoeven, L.; Adam, J.J.; van Kranenburg, J.; Nilwik, R.; van Loon, L.J. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. *J. Am. Med. Dir. Assoc.* **2013**, *14*, 585–592. [[CrossRef](#)]
100. Ogama, N.; Sakurai, T.; Kawashima, S.; Tanikawa, T.; Tokuda, H.; Satake, S.; Miura, H.; Shimizu, A.; Kokubo, M.; Niida, S.; et al. Association of Glucose Fluctuations with Sarcopenia in Older Adults with Type 2 Diabetes Mellitus. *J. Clin. Med.* **2019**, *8*, 319. [[CrossRef](#)]
101. Navarro-Flores, E.; Pérez-Ros, P.; Martínez-Arnau, F.M.; Julián-Rochina, I.; Cauli, O. Neuro-Psychiatric Alterations in Patients with Diabetic Foot Syndrome. *CNS Neurol. Disord. Drug Targets* **2019**, *18*, 598–608. [[CrossRef](#)]
102. Simón-Pérez, E.; Simón-Pérez, C.; Alonso-Peña, D.; Pontón-Cortina, A.; Chicharro-Luna, E.; Martínez-Nova, A.; Navarro-Flores, E. Stiffness degree of ankle range of motion in diabetic patients with atypical amputation. *Rev. Assoc. Med. Bras.* **2020**, *66*, 216–221. [[CrossRef](#)] [[PubMed](#)]
103. Kim, Y.K.; Lee, H.S.; Ryu, J.J.; Seo, S.G. Sarcopenia increases the risk for mortality in patients who undergo amputation for diabetic foot. *J. Foot Ankle Res.* **2018**, *11*, 32. [[CrossRef](#)] [[PubMed](#)]
104. Beaudart, C.; Sanchez-Rodriguez, D.; Locquet, M.; Reginster, J.; Lengelé, L.; Bruyère, O. Malnutrition as a Strong Predictor of the Onset of Sarcopenia. *Nutrients* **2019**, *11*, 2883. [[CrossRef](#)] [[PubMed](#)]
105. Morley, J.E.; Malmstrom, T.K.; Rodríguez-Mañas, L.; Sinclair, A.J. Frailty, sarcopenia and diabetes. *J. Am. Med. Dir. Assoc.* **2014**, *15*, 853–859. [[CrossRef](#)]
106. Smith, G.I.; Atherton, P.; Reeds, D.N.; Mohammed, B.S.; Rankin, D.; Rennie, M.J.; Mittendorfer, B. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: A randomized controlled trial. *Am. J. Clin. Nutr.* **2011**, *93*, 402–412. [[CrossRef](#)]
107. Smith, G.I.; Atherton, P.; Reeds, D.N.; Mohammed, B.S.; Rankin, D.; Rennie, M.J.; Mittendorfer, B. Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia-hyperaminoacidaemia in healthy young and middle-aged men and women. *Clin. Sci.* **2011**, *121*, 267–278. [[CrossRef](#)]
108. Kitajka, K.; Sinclair, A.J.; Weisinger, R.S.; Weisinger, H.S.; Mathai, M.; Jayasooriya, A.P.; Halver, J.E.; Puskás, L.G. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 10931–10936. [[CrossRef](#)]
109. Ganapathy, A.; Nieves, J.W. Nutrition and Sarcopenia—What Do We Know? *Nutrients* **2020**, *6*, 1775. [[CrossRef](#)]
110. Della Pepa, G.; Brandi, M. Microelements for bone boost: The last but not the least. *Clin. Cases Miner. Bone Metab.* **2016**, *3*, 181–185. [[CrossRef](#)]
111. Tang, J.E.; Moore, D.R.; Kujbida, G.W.; Tarnopolsky, M.A.; Phillips, S.M. Ingestion of whey hydrolysate, casein, or soy protein isolate: Effects on mixed muscle protein synthesis at rest and following resistance exercise in young men. *J. Appl. Physiol.* **2009**, *107*, 987–992. [[CrossRef](#)] [[PubMed](#)]

112. Hamarsland, H.; Nordengen, A.L.; Aas, S.N.; Holte, K.; Garthe, I.; Paulsen, G.; Cotter, M.; Børsheim, E.; Benestad, H.B.; Raastad, T. Native whey protein with high levels of leucine results in similar post-exercise muscular anabolic responses as regular whey protein: A randomized controlled trial. *J. Int. Soc. Sports Nutr.* **2017**, *14*, 43. [[CrossRef](#)] [[PubMed](#)]
113. Martínez-Arnau, F.M.; Fonfría-Vivas, R.; Cauli, O. Beneficial Effects of Leucine Supplementation on Criteria for Sarcopenia: A Systematic Review. *Nutrients* **2019**, *11*, 2504. [[CrossRef](#)] [[PubMed](#)]
114. Ding, M.; Bhupathiraju, S.N.; Chen, M.; van Dam, R.M.; Hu, F.B. Caffeinated and Decaffeinated Coffee Consumption and Risk of Type 2 Diabetes: A Systematic Review and a Dose-Response Meta-analysis. *Diabetes Care* **2014**, *37*, 569–586. [[CrossRef](#)] [[PubMed](#)]
115. Carlström, M.; Larsson, S.C. Coffee consumption and reduced risk of developing type 2 diabetes: A systematic review with meta-analysis. *Nutr. Rev.* **2018**, *76*, 395–417. [[CrossRef](#)]
116. Chung, H.; Moon, J.H.; Kim, J.I.; Kong, M.H.; Huh, J.S.; Kim, H.J. Association of Coffee Consumption with Sarcopenia in Korean Elderly Men: Analysis Using the Korea National Health and Nutrition Examination Survey, 2008–2011. *Korean J. Fam. Med.* **2017**, *38*, 141–147. [[CrossRef](#)]
117. Kim, J.H.; Park, Y.S. Light coffee consumption is protective against sarcopenia, but frequent coffee consumption is associated with obesity in Korean adults. *Nutr. Res.* **2017**, *41*, 97–102. [[CrossRef](#)]
118. Dirks-Naylo, A.J. The benefits of coffee on skeletal muscle. *Life Sci.* **2015**, *143*, 182–186. [[CrossRef](#)]
119. Mijnders, D.M.; Koster, A.; Schols, J.M.G.A.; Meijers, J.M.M.; Halfens, R.J.G.; Gudnason, V.; Eiriksdottir, G.; Siggeirsdottir, K.; Sigurdsson, S.; Jónsson, P.V.; et al. Physical activity and incidence of sarcopenia: The population-based AGES—Reykjavik Study. *Age Ageing* **2016**, *45*, 614–621. [[CrossRef](#)]
120. Kim, H.; Suzuki, T.; Kim, M.; Kojima, N.; Yoshida, Y.; Hirano, H.; Saito, K.; Iwasa, H.; Shimada, H.; Hosoi, E.; et al. Incidence and Predictors of Sarcopenia Onset in Community-Dwelling Elderly Japanese Women: 4-Year Follow-Up Study. *J. Am. Med. Dir. Assoc.* **2015**, *16*, e1–e8. [[CrossRef](#)]
121. Salminen, A.; Kaarniranta, K.; Kauppinen, A. Age-related changes in AMPK activation: Role for AMPK phosphatases and inhibitory phosphorylation by upstream signaling pathways. *Ageing Res. Rev.* **2016**, *28*, 15–26. [[CrossRef](#)] [[PubMed](#)]
122. Cetrone, M.; Mele, A.; Tricarico, D. Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II. *Curr. Diabetes Rev.* **2014**, *10*, 231–237. [[CrossRef](#)] [[PubMed](#)]
123. Lee, C.G.; Boyko, E.J.; Barrett-Connor, E.; Miljkovic, I.; Hoffman, A.R.; Everson-Rose, S.A.; Lewis, C.E.; Mannen Cawthon, P.; Strotmeyer, E.S.; Orwoll, E.S. Osteoporotic Fractures in Men (MrOS) Study Research Group. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. *Diabetes Care* **2011**, *34*, 2381–2386. [[CrossRef](#)] [[PubMed](#)]